Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Review of Ongoing Clinical Trials in Non-small Cell Lung Cancer A Status Report for 2009 from the ClinicalTrials.gov

Review of Ongoing Clinical Trials in Non-small Cell Lung Cancer A Status Report for 2009 from the... STATUS REPORT FOR CLINICAL TRIALS Review of Ongoing Clinical Trials in Non-small Cell Lung Cancer A Status Report for 2009 from the ClinicalTrials.gov Website Janakiraman Subramanian, MD,* Anusha R. Madadi, MD,† Monica Dandona, MD,‡ Kristina Williams,* Daniel Morgensztern, MD,*§ and Ramaswamy Govindan, MD*§ trials account for 14% of ongoing oncology trials worldwide Introduction: Several new agents are being tested in clinical trials is a testament to the vigorous interest in pursuing novel for patients with non-small cell lung cancer (NSCLC). A survey of treatment options for this disease. ongoing clinical trials in NSCLC in the ClinicalTrials.gov website Successful introduction of a new anticancer drug in the would help identify areas that require further attention in the future. United States requires regulatory approval by the Food and Methods: We conducted a survey of ongoing clinical trials on NSCLC Drug Administration. It takes more than 9 years to complete registered in the ClinicalTrials.gov website. The advanced search op- the required preclinical studies and a series of clinical trials. tion was applied using the terms “non small cell lung cancer,” “open Drug development is an expensive process, more specifi- studies,” “interventional,” and “adults 18 years or older.” cally, the clinical trials are http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Thoracic Oncology Wolters Kluwer Health

Review of Ongoing Clinical Trials in Non-small Cell Lung Cancer A Status Report for 2009 from the ClinicalTrials.gov

Govindan, Ramaswamy
Journal of Thoracic Oncology , Volume 5 (8) – Aug 1, 2010
Download PDF
4 pages

Loading next page...
 
/lp/wolters-kluwer-health/review-of-ongoing-clinical-trials-in-non-small-cell-lung-cancer-a-mC8YAWMsU7

References (19)

ISSN
1556-0864
DOI
10.1097/JTO.0b013e3181e76159
pmid
20592626
Publisher site
See Article on Publisher Site

Abstract

STATUS REPORT FOR CLINICAL TRIALS Review of Ongoing Clinical Trials in Non-small Cell Lung Cancer A Status Report for 2009 from the ClinicalTrials.gov Website Janakiraman Subramanian, MD,* Anusha R. Madadi, MD,† Monica Dandona, MD,‡ Kristina Williams,* Daniel Morgensztern, MD,*§ and Ramaswamy Govindan, MD*§ trials account for 14% of ongoing oncology trials worldwide Introduction: Several new agents are being tested in clinical trials is a testament to the vigorous interest in pursuing novel for patients with non-small cell lung cancer (NSCLC). A survey of treatment options for this disease. ongoing clinical trials in NSCLC in the ClinicalTrials.gov website Successful introduction of a new anticancer drug in the would help identify areas that require further attention in the future. United States requires regulatory approval by the Food and Methods: We conducted a survey of ongoing clinical trials on NSCLC Drug Administration. It takes more than 9 years to complete registered in the ClinicalTrials.gov website. The advanced search op- the required preclinical studies and a series of clinical trials. tion was applied using the terms “non small cell lung cancer,” “open Drug development is an expensive process, more specifi- studies,” “interventional,” and “adults 18 years or older.” cally, the clinical trials are

Journal

Journal of Thoracic Oncology – Wolters Kluwer Health

Published: Aug 1, 2010

There are no references for this article.